Harrow, Inc. (HROW)Healthcare | Drug Manufacturers - Specialty & Generic | Nashville, United States | NasdaqGM
28.76 USD
+1.51
(5.562%)
⇧
(Oct. 15, 2026, 11:16 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:14 a.m. EDT
The investment case for Harrow is currently fractured between a compelling long-term narrative and deteriorating operational reality. Fundamentally, the company is trapped in a value trap: despite a massive 10x price surge over the last decade driven by clinical success, the most recent annual performance was a sharp decline, and the balance sheet is fragile with debt-to-equity exceeding 2,000%. The market has priced in a severe correction, yet the business still burns cash with negative operating margins and no dividend to cushion the blow. Short-term, the stock is technically weak, trading well below its 50-day and 200-day averages, which suggests lingering selling pressure. While the options market shows significant interest in a rebound to $40+, the heavy put volume at lower strikes acts as a brake on any rapid advance. The statistical forecast models are too noisy to offer guidance here. Investors should view this as a high-risk speculative play on a potential clinical catalyst rather than a stable compounder; the current fundamentals do not support a 'buy and hold' thesis until profitability is restored. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.190163 |
| AutoTheta | 0.317773 |
| AutoARIMA | 0.423909 |
| MSTL | 0.435894 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 2.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.341 |
| Excess Kurtosis | -0.02 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2025.894 |
| Revenue per Share | 7.398 |
| Market Cap | 1,077,963,008 |
| Forward P/E | 10.37 |
| Beta | 0.19 |
| Profit Margins | -13.51% |
| Previous Name | Harrow Health, Inc. |
| Website | https://www.harrow.com |
As of Oct. 10, 2026, 6:14 a.m. EDT: Speculators are positioning for a volatile range-bound scenario rather than a decisive breakout. Call volume is heavily skewed toward out-of-the-money strikes (35, 40, 50), suggesting a bullish bias for a rally to $40-$50, yet put volume is equally aggressive at lower strikes (15, 20, 29), creating a dense 'wall' of protection. This heavy bid on both sides indicates uncertainty; traders are buying insurance against a drop while simultaneously betting on a recovery, reflecting a lack of consensus on immediate direction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2816456 |
| Address1 | 1A Burton Hills Boulevard |
| Address2 | Suite 200 |
| All Time High | 140.0 |
| All Time Low | 0.5 |
| Ask | 51.2 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 683,620 |
| Average Daily Volume3 Month | 584,923 |
| Average Volume | 584,923 |
| Average Volume10Days | 683,620 |
| Beta | 0.185 |
| Bid | 28.48 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 0.406 |
| City | Nashville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 28.755 |
| Current Ratio | 2.244 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 28.84 |
| Day Low | 27.03 |
| Debt To Equity | 2,025.894 |
| Display Name | Harrow |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,449,600 |
| Earnings Call Timestamp Start | 1,786,449,600 |
| Earnings Timestamp | 1,786,392,000 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | 17,715,000 |
| Ebitda Margins | 0.06428 |
| Enterprise To Ebitda | 69.785 |
| Enterprise To Revenue | 4.486 |
| Enterprise Value | 1,236,241,024 |
| Eps Current Year | 0.43333 |
| Eps Forward | 2.7725 |
| Eps Trailing Twelve Months | -0.99 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 35.6328 |
| Fifty Day Average Change | -6.877802 |
| Fifty Day Average Change Percent | -0.19301884 |
| Fifty Two Week Change Percent | -28.16456 |
| Fifty Two Week High | 54.85 |
| Fifty Two Week High Change | -26.095 |
| Fifty Two Week High Change Percent | -0.47575206 |
| Fifty Two Week Low | 26.96 |
| Fifty Two Week Low Change | 1.7950001 |
| Fifty Two Week Low Change Percent | 0.066580124 |
| Fifty Two Week Range | 26.96 - 54.85 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,190,986,200,000 |
| Float Shares | 28,929,749 |
| Forward Eps | 2.7725 |
| Forward P E | 10.371506 |
| Free Cashflow | -5,490,125 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 373 |
| Fullday Change | 1.5149994 |
| Fullday Change Percent | 5.5616717 |
| Fullday Price | 28.755 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.73280996 |
| Gross Profits | 201,958,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15378 |
| Held Percent Institutions | 0.58558 |
| Implied Shares Outstanding | 37,487,850 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,360,281,600 |
| Last Split Factor | 1:5 |
| Long Business Summary | Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. |
| Long Name | Harrow, Inc. |
| Market | us_market |
| Market Cap | 1,077,963,008 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_21993612 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-15 |
| Net Income To Common | -37,226,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,260,341,517 |
| Number Of Analyst Opinions | 9 |
| Open | 27.14 |
| Operating Cashflow | 6,252,000 |
| Operating Margins | -0.15577 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 615 733 4730 |
| Prev Name | Harrow Health, Inc. |
| Previous Close | 27.24 |
| Price Eps Current Year | 66.3582 |
| Price Hint | 2 |
| Price To Book | 70.82513 |
| Price To Sales Trailing12 Months | 3.911417 |
| Profit Margins | -0.13508001 |
| Quick Ratio | 1.995 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 1.5149994 |
| Regular Market Change Percent | 5.5616717 |
| Regular Market Day High | 28.84 |
| Regular Market Day Low | 27.03 |
| Regular Market Day Range | 27.03 - 28.84 |
| Regular Market Open | 27.14 |
| Regular Market Previous Close | 27.24 |
| Regular Market Price | 28.755 |
| Regular Market Time | 1,792,077,389 |
| Regular Market Volume | 141,318 |
| Return On Assets | -0.00451 |
| Return On Equity | -1.1607 |
| Revenue Growth | 0.109 |
| Revenue Per Share | 7.398 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 37,487,850 |
| Shares Percent Shares Out | 0.20709999 |
| Shares Short | 7,762,798 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,778,977 |
| Short Name | Harrow, Inc. |
| Short Percent Of Float | 0.23040001 |
| Short Ratio | 13.98 |
| Source Interval | 15 |
| State | TN |
| Symbol | HROW |
| Target High Price | 88.0 |
| Target Low Price | 45.0 |
| Target Mean Price | 65.0 |
| Target Median Price | 60.0 |
| Total Cash | 85,317,000 |
| Total Cash Per Share | 2.276 |
| Total Debt | 300,744,000 |
| Total Revenue | 275,593,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.99 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 39.63695 |
| Two Hundred Day Average Change | -10.881952 |
| Two Hundred Day Average Change Percent | -0.2745406 |
| Type Disp | Equity |
| Volume | 141,318 |
| Website | https://www.harrow.com |
| Zip | 37,215 |